We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly & Company (NYSE:LLY) ranks among the stocks to invest in before they split next. Truist Securities restated its Buy rating and $1,281 price target for Eli Lilly & Company (NYSE:LLY) shares on April 17, following encouraging Phase 3 trial outcomes for Foundayo in type 2 diabetes. Eli Lilly & Company (NYSE:LLY) reported the […]
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 55.5% year on year to $19.8 billion. The company’s full-year revenue guidance of $83.5 billion at the midpoint came in 2.1% above analysts’ estimates. Its non-GAAP profit of $8.55 per share was 25.9% above analysts’ consensus estimates.
Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest pharmaceutical winners, even as analysts continue to weigh how much growth is already priced into the stock. Bank of America reiterated its Buy rating on Eli Lilly and set a $1,133 ...
Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug development.
Eli Lilly and Company (NYSE:LLY) executives said the drugmaker started 2026 with “a strong start,” pointing to sharp first-quarter revenue growth, continued demand for its incretin medicines, a newly approved oral obesity therapy, and a slate of pipeline and business development milestones. Founday
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.
Veeva Systems stock pops following S&P 500 inclusion announcement.
Eli Lilly (LLY) reported strong Q1 results driven by GLP-1 drugs, with fundamentals remaining solid
Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, w
Assessing Eli Lilly after a strong multi year run Eli Lilly (LLY) is back in focus for many investors after a long stretch of strong multi year total returns and significant scale, with a market value around US$761.7b and annual revenue of US$65.2b. See our latest analysis for Eli Lilly. The latest 9.8% 1 day share price return takes Eli Lilly to US$934.60, while the 1 year total shareholder return of 18.56% and 5 year total shareholder return above 4x suggest long term momentum has remained...
Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.
Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali